Form 8-K - Current report:
SEC Accession No. 0001764013-21-000102
Filing Date
2021-09-27
Accepted
2021-09-27 08:23:54
Documents
21
Period of Report
2021-09-27
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K imvt-20210927.htm   iXBRL 8-K 36418
2 EX-99.1 exhibit991-20210927.htm EX-99.1 4386
3 EX-99.2 roivantpipelineday2021.htm EX-99.2 9540
7 GRAPHIC roivantpipelineday2021001.jpg GRAPHIC 70187
8 GRAPHIC roivantpipelineday2021002.jpg GRAPHIC 217048
9 GRAPHIC roivantpipelineday2021003.jpg GRAPHIC 88863
10 GRAPHIC roivantpipelineday2021004.jpg GRAPHIC 107864
11 GRAPHIC roivantpipelineday2021005.jpg GRAPHIC 122267
12 GRAPHIC roivantpipelineday2021006.jpg GRAPHIC 76179
13 GRAPHIC roivantpipelineday2021007.jpg GRAPHIC 105910
  Complete submission text file 0001764013-21-000102.txt   1278679

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT imvt-20210927.xsd EX-101.SCH 1908
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT imvt-20210927_lab.xml EX-101.LAB 23970
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT imvt-20210927_pre.xml EX-101.PRE 12642
14 EXTRACTED XBRL INSTANCE DOCUMENT imvt-20210927_htm.xml XML 10825
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38906 | Film No.: 211279032
SIC: 2836 Biological Products, (No Diagnostic Substances)